Who Owns Apellis Pharmaceuticals Company?

Who owns Apellis Pharmaceuticals?

Apellis shifted from clinical-stage to commercial after Syfovre's FDA approval, drawing intense investor focus. Ownership reveals who backs its C3 platform as it scales and manages safety and market risks.

Founded in 2009 and based in Waltham, MA, Apellis grew from founder and VC control to broad institutional and public ownership; market cap was about $5.8 billion in early 2025. See Apellis Pharmaceuticals Porter's Five Forces Analysis for related strategic context.

Founders and Early Ownership of Apellis Pharmaceuticals trace to 2009 when Cedric Francois and Pascal Deschatelets launched the company, combining clinical and chemistry expertise and retaining significant founder stakes amid early venture funding.

Founders

Cedric Francois served as President and CEO and Pascal Deschatelets as Chief Scientific Officer, both bringing prior collaboration from Potentia Pharmaceuticals.

Early Ownership Stakes

Initial filings and regulatory disclosures indicated founders held a combined minority stake typically estimated between 10 and 20 percent to align long-term scientific goals with investors.

Lead Investors

Morningside Venture Investments (Chan family) led Series A/B rounds, providing the primary capital that enabled pegcetacoplan’s early clinical development.

Other Early Backers

Notable early investors included AJU IB Investment and Epidarex Capital, each taking typical venture protections and board rights common in biotech startups.

Governance

Early financing agreements included standard founder vesting schedules and protective provisions for venture backers, concentrating control with institutional investors during initial growth.

Strategic Focus

Venture oversight emphasized advancement of the C3 inhibition pathway, ensuring resources and board guidance were aligned with clinical milestones.

Early ownership and investor composition set the stage for subsequent public shareholder distributions when the company later pursued broader financing and eventual public listing processes.

Key facts

Founders, lead investors and governance during Apellis’ early years shaped its trajectory from private startup to a company with public shareholder participation.

• Cofounders: Cedric Francois (CEO) and Pascal Deschatelets (CSO)
• Founders’ combined early stake estimated at 10–20%
• Lead early investor: Morningside Venture Investments (Chan family)
• Other early investors: AJU IB Investment, Epidarex Capital

For deeper strategic context on investor influence and ownership evolution see Growth Strategy of Apellis Pharmaceuticals

Complete Apellis Pharmaceuticals Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events shaping Apellis Pharmaceuticals ownership include the November 2017 Nasdaq Global Select Market IPO that raised approximately $150,000,000, subsequent secondary offerings to fund global launches and Phase 3 programs, and steady institutional accumulation leading to concentrated stewardship by investment firms by January 2025.

By January 2025 institutional investors collectively hold over 92% of outstanding shares, reflecting the current ownership structure of Apellis Pharmaceuticals and the transition from founder/private equity control to public, institution-driven governance.

Major ownership dynamics

Institutional concentration drives strategic decisions, proxy outcomes, and board composition as Apellis scales commercialization and Phase 3 development.

• IPO in November 2017 raised about $150M
• Institutional holders own > 92% of shares (Jan 2025)
• Top holders: FMR (~13.5%), Vanguard (~9.2%), BlackRock (~8.1%)
• Specialized funds pivot on clinical readouts and Syfovre performance

For context on competitive positioning and investor implications see Competitors Landscape of Apellis Pharmaceuticals.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The current board of directors of Apellis Pharmaceuticals combines scientific founders and investors, led by co-founder Cedric Francois and including representatives from early backers; the board maintains a majority of independent directors under Nasdaq standards to align governance with the interests of a largely institutional shareholder base.

Apellis Pharmaceuticals ownership is dominated by institutions, with approximately 92% of outstanding shares held by institutional investors as of 2025 filings; the company uses a single‑class common stock structure—one share, one vote—so voting power maps directly to share ownership.

Board balance and voting clarity

The board mixes founders and investor representatives while maintaining independent oversight to protect public shareholders and governance standards.

• Single class common stock: one vote per share
• No dual‑class or golden shares; standard public accountability
• Institutional investors hold the bulk of voting power, enabling direct engagement
• Activist investors can influence strategy during volatility due to transparent voting

For context on market strategy and investor targeting tied to governance, see Target Market of Apellis Pharmaceuticals.

Apellis Pharmaceuticals Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

From 2022 through early 2025, Apellis Pharmaceuticals ownership shifted toward healthcare-focused institutions as Syfovre commercial uptake and safety stability encouraged consolidation; early venture investors reduced stakes while long-only funds and index trackers increased exposure. Secondary offerings in 2023–2024 raised cash but caused modest dilution, extending the company’s runway.

Apellis Pharmaceuticals shareholders now skew toward institutional holders, improving liquidity and making the company an attractive acquisition candidate while management hires signal a tilt to commercial execution and potential strategic exit options; see Revenue Streams & Business Model of Apellis Pharmaceuticals for related context.

Institutional ownership rise

Major institutional investors increased stakes following Syfovre uptake; this supports share liquidity and potential tender-offer dynamics.

Secondary raises and cash runway

Secondary offerings during 2023–2024 boosted cash to about $800,000,000, trading modest dilution for extended funding of commercialization.

Board and leadership evolution

Departures of long-tenured board members and appointments of executives with Biogen/Roche backgrounds point to stronger commercial focus in Apellis Pharmaceuticals leadership.

M&A positioning

High institutional ownership and solidifying commercial metrics make the company a plausible acquisition target for firms expanding ophthalmology or rare-disease portfolios.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE